Similar Search Results

Grinols, Earl L.; Henderson, James W. - In: PharmacoEconomics 25 (2007) 5, pp. 355-363

were unavailable. Superior mechanisms lie somewhere between a first best pricing solution for the entire economy at one … intertemporal bounty is the best way to meet the multiple objectives of immediate distribution at marginal cost pricing of newly …

Persistent link: https://www.econbiz.de/10005590430

Assessing the Impact of Global Price Interdependencies

Richter, Anke - In: PharmacoEconomics 26 (2008) 8, pp. 649-659

pricing and parallel trade. Behaviours that are optimal in the single, individual game (for either the country or the … the firm's launch and pricing decisions is presented along with examples wherein international price dependencies most … likely played a role. This model can help countries understand the implication of their external reference pricing policies …

Persistent link: https://www.econbiz.de/10005404838

Future Drug Prices and Cost-Effectiveness Analyses

Hoyle, Martin - In: PharmacoEconomics 26 (2008) 7, pp. 589-602

Background: Cost-effectiveness analyses worldwide assume that the price of any single drug increases with inflation. New guidance from the Pharmaceutical Management Agency in New Zealand suggests that, when it is known that a generic drug will be available in the near future, a best estimate of...

Persistent link: https://www.econbiz.de/10005404867

Reform of Prescription Drug Reimbursement and Pricing in the German Social Health Insurance Market: A Comparison of Three Scenarios

Gress, Stefan; Niebuhr, Dea; May, Uwe; Wasem, Jurgen - In: PharmacoEconomics 25 (2007) 6, pp. 443-454

: regulation of reimbursement and pricing. We find that centralised regulation of reimbursement and pricing prevails in the 15 … centralised pricing; the second maintains centralised reimbursement but switches to decentralised pricing (similar to social … discounts and market shares for genetic and therapeutic substitutes. In the third scenario, pricing and reimbursement would be …

Persistent link: https://www.econbiz.de/10005404890

Waiting for Reimbursement of New Medicines in Canada: It's Time for a Rethink

Skinner, Brett J. - In: PharmacoEconomics 26 (2008) 8, pp. 629-632

Available evidence indicates that patients who have private sector drug insurance are immediately covered for all new medically necessary drugs certified by Health Canada, with few exceptions. The experience for patients who are dependent on public drug programmes is much worse. Evidence...

Persistent link: https://www.econbiz.de/10005449295

Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies

Godman, Brian; Haycox, Alan; Schwabe, Ulrich; Joppi, Roberta - In: PharmacoEconomics 26 (2008) 2, pp. 91-98

the provision of other priority services. The UK Office of Fair Trading (OFT) recently suggested a value-based pricing … the prices of generics in a class or related classes, is also more generous than the proposed reforms for the pricing of …

Persistent link: https://www.econbiz.de/10005449303

The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?

Fattore, Giovanni; Jommi, Claudio - In: PharmacoEconomics 26 (2008) 1, pp. 5-15

principles for reimbursement and pricing, and the use of generic drugs to lower prices. As a result of these changes …

Persistent link: https://www.econbiz.de/10004990333

Pricing Human Papillomavirus Vaccines: Lessons from Italy

Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: PharmacoEconomics 30 (2012) 3, pp. 213-217

Persistent link: https://www.econbiz.de/10009493380

Hospital Reimbursement Price Cap for Cancer Drugs: The French Experience in Controlling Hospital Drug Expenditures

Degrassat-Théas, A. Degrassat-Thas; Bensadon, M.; Rieu, C. - In: PharmacoEconomics 30 (2012) 7, pp. 565-573

Background:Background: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimbursement price cap. Hospitals still negotiate with...

Persistent link: https://www.econbiz.de/10011005079

Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms

Golec, Joseph; Vernon, John A. - In: PharmacoEconomics 28 (2010) 8, pp. 615-628

EU countries closely regulate pharmaceutical prices, whereas the US does not. This paper shows how price constraints affect the profitability, stock returns and R&D spending of EU and US firms. Compared with EU firms, US firms are more profitable, earn higher stock returns and spend more on R&D....

Persistent link: https://www.econbiz.de/10008465562